Funding for this research was provided by:
National Institute for Health Research (PB-PG-0815-20053)
Received: 11 August 2020
Accepted: 18 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: The trial was reviewed by the London South East Research Ethics Committee and received a favourable opinion on 23 November 2018. All participants provided informed consent to participate.
: JStr and SP have contributed to UK guidelines on the potential role of contingency management in the management of opioid addiction (NICE, 2007; convened by SP, chaired by JStr). SP receives funding from NICE for the production of clinical guidelines. JS has chaired the broader-scope pan-UK working group preparing the 2017 and 2007 Orange Guidelines for the UK Departments of Health and Social Care, providing guidance on management and treatment of drug dependence and misuse, including guidance on possible inclusion of contingency management. JSc was a member of this group.JStr is a researcher and clinician who, through his university, has worked with various pharmaceutical companies to identify new or improved treatments and his employer (King’s College London) has received grants, travel costs, and/or consultancy payments from companies including, past 3 years, Indivior, Mundipharma, Camurus, Molteni Farma, and Accord. JStr has also worked with various drug policy organisations and advisory bodies including the Society for the Study of Addiction (SSA), and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).JStr and KG are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. JStr is an NIHR Senior Investigator. For a fuller account, see JStr’s web-page at ExternalRef removedNM, through her employer (King’s College London), has received a grant from a pharmaceutical company MundiPharma Research Ltd.